Opko Health opened at $1.71, in line with its previous close of $1.71. In the last trading session, the stock traded between $1.66 and $1.74. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Opko Health is now worth
$ 40.71
Resulting in a loss of
$ 59.29 (59.29%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.05 (-2.63%)
Day High
$1.74
Day Low
$1.66
Day Open
$1.71
Prev Close
$1.71
Volume
22,66,744
1W Return
-6.77%
1M Return
21.09%
3M Return
19.35%
6M Return
48.66%
1Y Return
25.19%
Fundamentals
Market Cap ($ Mn)
1,236
PE Ratio
-
PB Ratio
0.94
PEG Ratio
-
ROE
-17.23%
ROCE
-7.98%
EPS (TTM)
$-0.07
Investment Returns
1 Week
-6.77%
1 Month
21.09%
3 Months
19.35%
6 Months
48.66%
9 Months
33.20%
Financials
Quarterly
All values in $ Mn
156.8
Jun 25
151.7
Sep 25
148.4
Dec 25
124.2
Mar 26
163.6
Jun 26
65.4
Sep 26
Updates
5Nov
OPKO Health forecasts Q4 sales of $62 million to $72 million
OPKO Health Inc. projects Q4 sales between $62.000 million and $72.000 million. The guidance provides a specific revenue range for the fourth quarter.
8 days ago
5Nov
OPKO Health Q3FY26 Results: Loss narrows to $(0.05), revenue up 16%
Revenue from continuing operations rose 16% YoY to $65.4 million in Q3FY26. Full-year FY26 revenue guidance maintained at $268 million to $278 million. Net loss narrowed to $(0.05) per share, beating consensus estimate of $(0.06). Sale of BioReference assets to LabCorp valued at approximately $722 million.
8 days ago
16Oct
Piper Sandler raises OPKO Health price target to $4
Piper Sandler reiterated an Overweight rating on OPKO Health. Price target raised from $3 to $4. Analyst Edward Tenthoff issued the updated recommendation.
27 days ago
8Sep
OPKO Health executives to speak at Wells Fargo healthcare conference
OPKO Health executives will speak at the Wells Fargo 21st Annual Healthcare Conference. The fireside chat is scheduled for September 10, 2026, at 9:30 am ET. Elias A. Zerhouni and Adam Logal will represent the company. A webcast and replay will be available on the company's IR website.
2mo ago
13Aug
OPKO Health issues $125M senior secured notes to KKR's HCRx
OPKO Health secured $125 million in non-dilutive funding through senior secured notes issued to KKR's HCRx. Secured by mazdutide royalties from Eli Lilly, the notes mature in 2044. Payments are capped at 1.5x the funded amount, allowing OPKO to retain full upside thereafter.
3mo ago
28Jul
OPKO Health Q2 EPS beats estimates as sales rise 4.3% to $163.5 million
OPKO Health reported a Q2 loss of $(0.01) per share, beating estimates by 87.5%, while sales of $163.5 million exceeded expectations by 24.6%. The company narrowed its net loss to $8.4 million from $148.4 million year-over-year, driven by IP monetization and cost reductions post-Labcorp asset sale.
